Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.
The firm argues that its tests allows hospitals to expedite patient treatment, while curbing the costs of one-off tests and medication, and minimizing the length of a patient's stay.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
Natera alleged that certain cell-free DNA-based oncology products sold by Archer Dx infringe its US Patent 10,538,814, which was issued earlier this month.
GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.
The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.
